晚期ER阳性/HER2阴性乳腺癌中循环肿瘤DNA早期治疗演变的预后意义
在PADA-1试验的369例晚期ER阳性/HER2阴性乳腺癌患者中,于基线和治疗早期(中位28天)采集配对血浆,用497基因面板检测游离DNA。基线ctDNA水平及早期治疗中ctDNA动态均与PFS和OS相关;整合基线与动态ctDNA特征的风险模型在RECIST之外独立预后,并改善生存区分度。
要点
- 基线ctDNA平均VAF每增加1单位,PFS HR 1.07(95%CI 1.05-1.09,P<0.001),OS HR 1.08(95%CI 1.05-1.11,P<0.001)。
- 两个时间点VAF均>0.5%的驱动体细胞突变数:PFS HR 1.39(95%CI 1.27-1.53,P<0.001),OS HR 1.51(95%CI 1.35-1.68,P<0.001)。
- ctDNA风险模型在多变量模型中独立于RECIST预后:测试集OS HR 4.10(95%CI 1.93-8.72,P<0.001),PFS HR 1.86(95%CI 1.16-2.97,P=0.009)。
核心结论
- 早期治疗中ctDNA演变对晚期ER阳性/HER2阴性乳腺癌的PFS和OS均具有预后价值。
- 基于ctDNA的风险模型在传统RECIST和临床参数之上改善预后区分,倡导将ctDNA作为临床实践中的预后生物标志物。
研究设计与样本
- 研究为PADA-1试验中的配对血浆样本分析,纳入369例接受激素治疗联合CDK4/6抑制剂治疗的晚期ER阳性/HER2阴性乳腺癌患者。
- 于基线和治疗早期(中位28天)采集配对血浆,使用497基因面板(Guardant360 LDT)检测游离DNA。
主要发现
- 基线ctDNA平均VAF与PFS相关(HR 1.07,95%CI 1.05-1.09,P<0.001),与OS相关(HR 1.08,95%CI 1.05-1.11,P<0.001)。
- 基线驱动体细胞突变数与PFS相关(HR 1.13,95%CI 1.07-1.19,P<0.001),与OS相关(HR 1.16,95%CI 1.07-1.24,P<0.001)。
- 两个时间点VAF均>0.5%的驱动体细胞突变数与PFS相关(HR 1.39,95%CI 1.27-1.53,P<0.001),与OS相关(HR 1.51,95%CI 1.35-1.68,P<0.001)。
- VAF升高的驱动体细胞突变数与PFS相关(HR 1.31,95%CI 1.19-1.44,P<0.001),与OS相关(HR 1.10,95%CI 1.02-1.18,P=0.02)。
- ctDNA风险模型在多变量模型中独立于RECIST预后:测试集OS HR 4.10(95%CI 1.93-8.72,P<0.001),PFS HR 1.86(95%CI 1.16-2.97,P=0.009)。
关键数值与推荐
- 基线ctDNA平均VAF:PFS HR 1.07(95%CI 1.05-1.09,P<0.001),OS HR 1.08(95%CI 1.05-1.11,P<0.001)。
- 基线驱动体细胞突变数:PFS HR 1.13(95%CI 1.07-1.19,P<0.001),OS HR 1.16(95%CI 1.07-1.24,P<0.001)。
- 两个时间点VAF均>0.5%的驱动体细胞突变数:PFS HR 1.39(95%CI 1.27-1.53,P<0.001),OS HR 1.51(95%CI 1.35-1.68,P<0.001)。
- VAF升高的驱动体细胞突变数:PFS HR 1.31(95%CI 1.19-1.44,P<0.001),OS HR 1.10(95%CI 1.02-1.18,P=0.02)。
- 测试集ctDNA风险模型:OS HR 4.10(95%CI 1.93-8.72,P<0.001),PFS HR 1.86(95%CI 1.16-2.97,P=0.009)。
临床怎么用
- 作者倡导将ctDNA作为临床实践中的预后生物标志物。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients with advanced estrogen receptor-positive, HER2-negative breast cancer commonly develop resistance to treatment with hormone therapy and cyclin-dependent kinase 4/6 (CDK4/6) inhibitors. Responders cannot be distinguished from nonresponders after the first cycle of treatment under current practice. We assessed circulating tumor DNA (ctDNA) measures at early timepoints as prognostic markers. PATIENTS AND METHODS: Paired plasma samples were collected at baseline and early on-treatment (median 28 days) from 369 patients with advanced ER-positive/HER2-negative breast cancer treated in the PADA-1 trial with hormone therapy and a CDK4/6 inhibitor. Cell-free DNA was profiled with a 497-gene panel (Guardant360 LDT). RESULTS: Baseline ctDNA levels, including the mean variant allele frequency (VAF) [progression-free survival (PFS) hazard ratio (HR) 1.07, 95% confidence interval (CI) 1.05-1.09), P < 0.001; overall survival (OS) HR 1.08, 95% CI 1.05-1.11, P < 0.001] and the number of driver somatic mutations (PFS HR 1.13, 95% CI 1.07-1.19, P < 0.001; OS HR 1.16, 95% CI 1.07-1.24, P < 0.001) were prognostic. Early on-treatment ctDNA dynamics were also associated with outcomes, including the number of driver somatic mutations with VAF > 0.5% at both timepoints (PFS HR 1.39, 95% CI 1.27-1.53, P < 0.001; OS HR 1.51, 95% CI 1.35-1.68, P < 0.001) and the number of driver somatic mutations with a VAF increase (PFS HR 1.31, 95% CI 1.19-1.44, P < 0.001; OS HR 1.10, 95% CI 1.02-1.18, P = 0.02). A ctDNA-based risk model incorporating baseline and dynamic ctDNA features was independently prognostic from RECIST in multivariable models (test set: OS HR 4.10, 95% CI 1.93-8.72, P < 0.001; PFS HR 1.86, 95% CI 1.16-2.97, P = 0.009). The integration of ctDNA features into a clinical model improved survival discrimination for PFS [C-index 64.7% (± 2.5%) for a ctDNA and clinical model versus 59.3% (± 2.2%) for a clinical-only model, P = 0.027] and for OS [C-index 70.0% (± 3.4%) versus 60.3% (± 4.2%), P = 0.035]. CONCLUSIONS: Early on-treatment evolution of ctDNA is prognostic for both PFS and OS in advanced ER-positive/HER2-negative breast cancer. A ctDNA-based risk model improves upon traditional RECIST and clinical parameters, advocating for ctDNA as a prognostic biomarker in clinical practice.
引用
- Mamann A, Pradat Y, Bidard FC, et al. Prognostic significance of early on-treatment evolution of circulating tumor DNA in advanced ER-positive/HER2-negative breast cancer. Ann Oncol. 2025. PMID: 40623476. doi:10.1016/j.annonc.2025.06.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。